Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study
出版年份 2020 全文链接
标题
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study
作者
关键词
Durvalumab, Immunotherapy, Non–small cell, Stage III, Multimodality, Real-world
出版物
EUROPEAN JOURNAL OF CANCER
Volume 142, Issue -, Pages 83-91
出版商
Elsevier BV
发表日期
2020-11-24
DOI
10.1016/j.ejca.2020.10.008
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Therapeutic landscape of metastatic non-small-cell lung cancer in Canada in 2020
- (2020) A. Elkrief et al. Current Oncology
- Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
- (2020) Hyun Ae Jung et al. LUNG CANCER
- Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
- (2020) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
- (2019) Solange Peters et al. ANNALS OF ONCOLOGY
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- (2019) Jhanelle E. Gray et al. Journal of Thoracic Oncology
- Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
- (2018) Greg Andrew Durm et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Term Results of RTOG 0617: A Randomized Phase 3 Comparison of Standard Dose Versus High Dose Conformal Chemoradiation Therapy +/- Cetuximab for Stage III NSCLC
- (2017) J.D. Bradley et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- P3.04-003 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC
- (2017) H. Ross et al. Journal of Thoracic Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- (2016) Peter Goldstraw et al. Journal of Thoracic Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04
- (2015) Jin Seok Ahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Radiotherapy and Immunogenic Cell Death
- (2015) Encouse B. Golden et al. SEMINARS IN RADIATION ONCOLOGY
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
- (2011) W. J. Curran et al. JNCI-Journal of the National Cancer Institute
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started